The development of compounding drugs by mixed Chinese traditional and western medicine for treating disease has became important in China. Chinese tradition medicine was crude drugs with low side-effect and long-effect, but western medicine as chemical medicine usually effect in a short time and the aftereffect can be reversed of using Chinese traditional medicine. Many clinical and pharmacological experiments have proved that compounding drugs has the advantages of improving curative effects, reducing deleterious side-effects and shortening the period of treatment in relation to using Chinese traditional or western medicine separately.
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Diphenhydramine, 2-(diphenylmethoxy)-N,N-dimethylethanamine hydrochloride (DPH), a histamine H 1 -receptor antagonist is widely used as antiallergic, antiemetic and antitussive drug in many pharmaceutical preparations. 1 DPH is usually given in a preparation of tablet or drops or as an injection, either alone or in combination with other drugs (i.e. ephedrine, EPH). EPH is generally prepared from Ma huang, which is a traditional Chinese medicine derived from Ephedrae plant. It is used as a pharmaceutical for exciting the central nervous system, the systole of blood vessels, and the lysis of spasm of bronchial smooth muscles. Excessive DPH use could bring about symptoms of phrenitis, tic, tremor, low blood pressure and decompensation. As for babies and young children, it also could result in exciting them easily and causing hallucinations. Mixing DPH with EPH to create a compound drug can exert the good qualities of two drugs and reduce the side-effects of using DPH alone. In the pharmaceutical compound of DPH and EPH, the amount of DPH must be accurately monitored to avoid possible damage to human health due to an unreasonable mixture. Many analytical methods have been proposed for determining DPH in pharmaceutical samples including titrimetry, 2 fluorophotometry, 3 electrochemical analysis 4 and spectrophotometry, 5, 6 gas chromatography, 7 HPLC 8,9 and capillary electrophoresis. 10, 11 Indeed, the spectrophotometry and HPLC are used as a pharmacopoeial method. 8, 12 Nevertheless, the spectrophotometric methods are time consuming, especially for compounding a sample without prior separation; and those instruments are relatively high in cost. Additionally, these methods usually require extraction and complicated pretreatment procedures prior to analysis, resulting in use of some toxic reagents and excessive operation. Accordingly, to develop a rapidly and conveniently quantificational method of DPH in a pharmaceutical compound containing EPH has become a significant work.
Flow injection analysis (FIA) is well established as an excellent technique for rapid automated quantitative analysis that combines on-line chemical and physical sample treatments with a range of flow-through detection systems in an enclosed, continuous flow environment. 13 FIA does not require high cost equipment to overcome shortages of instruments in places where HPLC instruments are not available. On the other hand, electrochemiluminescence (ECL) is the production of light from an electrode surface when a suitable potential is applied to the ECL reagents. Among numerous applications, ECL has been used extensively in chemical and biologic analysis as a sensitive and selective detection method for various analytes. 14 In recent years, FIA and ECL have been linked together to develop an FIA-ECL analytical method to join the advantages of FIA and ECL. 15 It becomes a method that is rapid, has good precision and uses small sample volumes. In this paper, we would like to report a FIA-ECL analysis for the determination of DPH in pharmaceutical samples composed by DPH or DPH and EPH, based the fact that on Ru(bpy)3 3+ oxidizes DPH to result in an enhancive ECL at a platinum electrode in the aqueous solution. This rapid, convenient characteristic of the method has been investigated and the ECL mechanism of the method has been discussed. 
Notes
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Experimental
Reagents
All solutions were prepared from analytical grade chemicals and deionized water (>15 MΩ) prepared from a KLUP-III water treatment system (Kang Ning Water Industry, China). Tris(2,2′-bipyridine)ruthenium(II) (Ru(bpy)3 2+ ) was purchased from Aldrich (Milwaukee, WI, USA). Its stock solution (1.0 × 10 -3 mol/L) was prepared in phosphate buffer, and stored in lightprotected bottles. Working solutions of Ru(bpy)3 2+ were prepared by diluting an appropriate amount stock solution with the phosphate buffer. DPH (purity ≥ 99%) and EPH (purity ≥ 98.0%) were obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). The stock solution (2.0 mg/ml) of DPH was also prepared in the phosphate buffer. Its low concentration standard solutions were freshly prepared from the stock solution by gradually diluting with the phosphate buffer before the experiment. All stock solutions and working solutions were stored at 4˚C.
Apparatus
A FIA-ECL analytical system was made of a flow injection analyzer (Shandong Seventh Telecommunication Co. Ltd., Jining, China) and an electrochemiluminescence analyzer equipped with an electrochemical meter and a data processing system (Remax Electronic Co. Ltd., Xi'an, China). Peristaltic pumps were used to deliver the carrier stream, and injection of both the mixed solution of sample with Ru(bpy)3 2+ and that of standard DPH with Ru(bpy)3 2+ was made using a six-way valve equipped with a 100-μl sample loop. The flow-cell was made of a polytetrafluoroethylene block fitted with three electrodes and a quartz window (diameter 6.0 mm). A platinum disk electrode (diameter 1.0 mm) was used as the working electrode. The counter electrode was a stainless-steel tube, an Ag/AgCl electrode was used as the reference electrode. The applied potential was controlled with an electrochemical meter and the ECL intensity was registered on a photometer. The photomultiplier tube (PMT) was operated at -800 V and the ECL flow-cell was placed directly in front of the PMT. Electrochemical operation and register of the ECL signal were directed from a personal computer.
Procedure
Before the first measurement was performed, the FIA-ECL analytical system was allowed to run for 5 min to achieve good mechanical and thermal stability. The 0.01 mol/L phosphate buffer of pH 7.2 as carrier stream was fed at a flow rate of 2.5 ml/min. A 1.10-V potential was applied to the working electrode with the electrochemical meter, and a solution of 1.0 × 10 -5 mol/L Ru(bpy)3 2+ as blank was injected into the carrier stream by the six-port valve, then a stable blank signal was observed. Then the mixed solutions of sample or standard DPH solutions with Ru(bpy)3 2+ was injected into the carrier stream, the ECL signal was recorded and the concentration of DPH was quantified by the peak height of the enhanced ECL emission intensity obtained by deducting the blank ECL intensity of the Ru(bpy)3 2+ from that with the sample or standard DPH solutions. The comparison HPLC analysis was performed with a P-3000 liquid chromatograph (Chuangxin Tongheng Science & Technology Co. Ltd., Beijing, China) in accordance with the literature. 9 
Treatment of practical samples
Pharmaceutical samples (tablet, drops and injections) were purchased from a drugstore. Liquid samples (drops and injections) were directly prepared to an appropriate concentration with the phosphate buffer. The sugar-coating of the tablet was removed, and then the tablet was grinded in a mortar and dissolved with 50 ml phosphate buffer in an ultrasonator for 10 min. Next, the solution was filtrated to remove insoluble substances and prepared to an appropriate concentration with the phosphate buffer. All sample solutions were mixed with Ru(bpy)3 2+ in convenient amounts for the determination of ECL.
Results and Discussion
ECL mechanism of selective determination of DPH
As is well known, amines, particularly tertiary amines, can observably promote ECL of Ru(bpy)3
2+ by acting as a coreactant. The ECL mechanism has been reported. 16 DPH is a basic nitrogenous compound, a tertiary amine, as shown in Fig. 1 , so it can also promote ECL of Ru(bpy)3 2+ in the same way.
Ru(bpy)3 2+ ⎯ → Ru(bpy)3 3+ + e -
Ru ( 
Here R is (C6H5)2CHOCH2CH2-, R′ is H3C-. But EPH is a secondary amine; apparently, its ECL activity is less than DPH. 17 As can be distinctly seen in Fig. 1 , EPH can not observably enhance ECL of Ru(bpy)3 2+ in comparison with DPH because of their different structures, unless EPH derivatives to a tertiary amine. Therefore, DPH could be selectively determined in the presence of EPH based on their capability to promote ECL of Ru(bpy)3
2+
. According to the mechanism of Ru(bpy)3 2+ ECL catalyzed by amines, 16 many factors affect the relative ECL intensity between DPH and EPE, such as the pH of the electrolytic solution, the applied potential and the concentration of Ru(bpy)3 2+ . From the ECL mechanism promoted with DPH, it is clear that the critical step in the ECL reaction is a deprotonation and subsequent oxidation of the amine to form a reducing radical intermediate. Apparently, deprotonation is easier; then the oxidation of the amine is easier. This is consistent with observations of the effect of pH on the ECL intensity presented by other authors. 18 , respectively. Although the ECL intensities are increased with increase of pH, never the less effect of DPH and EPH are different due to difference of their pKas. Because the pKas of DPH and EPH are 9.1 and 9.6, 19 respectively, the ECL intensity of DPH is relatively larger than that of EPH at a lower pH range. Along with the increase of pH, the difference of ECL intensity of DPH and EPH become gradually smaller. To selectively determine DPH in the present of EPH, the pH of 7.2 was selected as an optimum pH condition for all working solutions, after giving consideration to the pH dependence of substrates and to the blank ECL of Ru(bpy)3 2+ . Equatioins (2) and (4) indicate that an increase in the ECL intensity could be affected by promoting amine oxidation. Having more Ru(bpy)3 3+ on the electrode is propitious to oxidation of amine. In general, the ECL of Ru(bpy)3 2+ will increase with an increase of applied potential at electrode, reaching a maximal ECL intensity at about 1.10 -1.20 V. 16 But selective determination of DPH requires an appropriate potential to make the ECL intensity promoted by DPH is greater and that by EPH is smaller reversely. Our experimental results show that no emission was observed at the applied potential below 0.80 V; the ECL intensity increased gradually with the increasing of applied potential; the ECL intensities promoted by DPH and EPH reached a maximum when the applied potential at 1.10 and 1.20 V, respectively. So 1.10 V was selected for subsequent studies.
Initial tests showed that the ratio of the enhanced ECL signal of Ru(bpy)3 2+ to the blank ECL signal was dependent upon the Ru(bpy)3 2+ concentrations. Experimental results showed that the best concentration of Ru(bpy)3 2+ was 1.0 × 10 -5 mol/L, which was selected as the optimum concentration for determining other parameters.
Optimization of FIA conditions
The effect of flow rate on the intensity of ECL was studied over the range 1.0 -4.0 ml/min. The ECL intensity increases with an increase in flow rate but ECL peaks become very narrow to result in a lower accuracy when the flow rate is greater than 2.5 ml/min. So, an optimal flow rate of 2.5 ml/min was selected to maintain the maximum sensitivity and reproducibility for the subsequent experiments. After elaborating the ECL reaction conditions, we investigated the injection volume parameter. The variation of ECL emission with the injected sample volume in the 50 -150 μl range was studied. The results showed that higher ECL intensity was obtained by increasing loop volumes up to 100 μl for FIA-ECL system. Thus, in the present FIA-ECL system, a 100-μl loop was selected.
Quantitative analysis
Under the optimum conditions described above, Fig. 3 shows typical dynamic ECL responses to the blank solution of Ru(bpy)3 2+ and solution of DPH/Ru(bpy)3
2+
. As seen in the inset of Fig. 3 , the peak height of the enhanced ECL emission intensity is proportional to the concentration of DPH over the range of 2.00 to 40.0 μg/L, with a 1.20 μg/L detection limit (S/N = 3) and a correlation coefficient of 0.9995. The determination of DPH could be performed in 2 min including sampling and washing, giving a throughput of ca. 30 h -1 . The relative standard deviation was 3.8% for five repeated determinations of 16.0 μg/L DPH.
The effect of coexistent EPH was tested by analyzing a standard solution of 16.0 μg/L DPH to which increasing different amounts of interfering substance was added. The concentration ratios for a 5% ECL signal change are stipulated for a tolerable limit. Experimental results (Fig. 4) revealed that the determination of 16.0 μg/L DPH was not influenced by a less than 5 times excess of the added EPH. The tolerance of the method to supplement compounds probably presenting in pharmaceutical samples, such as farina, dextrin, sucrose, lactose, glucose, citric acid, magnesium stearate, or sodium chloride were investigated by adding various concentrations of the compounds to be tested. The results obtained (Table 1) indicate no interferential amount of the foreign compounds commonly presented together with DPH for the determination of 16.0 μg/L DPH.
The detection limit and the selectivity of the method allowed a direct determination of the DPH content in drops and injection samples, as well as tablet samples after dissolution and filtration. Each solution of samples was diluted appropriately with carrier solution and was mixed with the Ru(bpy)3 2+ solution before measurement. The DPH values in three different pharmaceutical samples were determined and are summarized in Table 2 along with the results of HPLC method for the comparison. The relative standard deviation was less than 4.6% to five parallel measurements of same sample, and the recovery was in the range of 98 -106%. As compared with the method of HPLC (the linear range, within 0.50 -5.0 μg/L; the recovery and RSD, 99.7 -108% (n = 6) and 1.0%; retention time, 12 min), 9 the proposed method is clearly applicable for determination of DPH in pharmaceutical samples mixed with ephedrine at thresholds above 1.20 μg/L and has a wider detecting range. Though it comes short of a simultaneously detecting ability for DPH and EPH, the method has advantages over HPLC method in terms of speed and convenience, economics, safe procedure and good sensitivity, and could be an alternative for places where HPLC equipment is not available. 
